A new article published in The Clinical Journal of Pain presented a narrative review of available and emerging prescription medications for opioid-induced constipation (OIC) in patients with chronic non-cancer pain, including concerns and challenges associated with OIC management. Here, the authors described opioid-induced constipation as changes in bowel habits and defecation patterns which occur when initiating opioid therapy and are associated with reduced bowel frequency, straining, sensation of incomplete evacuation, and/or patient distress related to bowel habits. It was stated that prescription medications are indicated when OIC persists despite conservative approaches like increased fiber and fluid intake, exercise, over-the-counter laxatives, and stool softeners. The article reported that Phase-3 studies have demonstrated the efficacy of peripherally acting µ-opioid receptor antagonists (peripherally acting μ-opioid receptor antagonist [PAMORA] - methylnaltrexone, naloxegol, naldemedine), and a chloride-channel activator (lubiprostone) for improving OIC in patients with chronic noncancer pain. Additionally, a meta-analysis demonstrated that μ-opioid receptor antagonists were more effective than placebo for the treatment of OIC. The most common adverse effects associated with prescription medications for OIC are gastrointestinal-related, such as nausea, diarrhea, abdominal pain or distention, although most are of mild or moderate in severity. Meanwhile, therapy currently in development for OIC includes the PAMORA axelopran. In inference, it was stated that healthcare providers should be aware of complications with opioid use and should monitor and address constipation-related symptoms to optimize pain management and improve patient quality of life.